

NOTICE OF ALLOWANCE IN UNITED STATES FOR PATENT PROTECTING AXIRON[®] APPLICATOR

Acrux (ASX: ACR) today reported that the United States Patent and Trademark Office has issued a Notice of Allowance for patent application number 11/678,673 “Spreading Implement”, with an anticipated expiry date of July 2029. Similar patent applications are pending in other pharmaceutical markets around the world.

This patent protects the applicator that is an integral part of the Axiron product and is used to apply the testosterone solution to the skin.

The Spreading Implement patent is part of a series of patents that protect the Axiron product. These include the pending patent application describing the underarm administration of testosterone, which is at an advanced stage of review in the United States.

Contact

Richard Treagus, CEO: 0417 520 509

About Acrux

www.acrux.com.au

- Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative technology to administer drugs through the skin.
- Fast-drying, invisible sprays or liquids provide a delivery platform with low or no skin irritation, superior cosmetic acceptability and simple, accurate and flexible dosing. The technology platform is covered by broad and well-differentiated, issued patents.
- Acrux has two products marketed by licensees in the USA, two products approved in Europe, one product in registration in the USA and further products at earlier stages of development.
- Acrux received two 2010 Governor of Victoria Export Awards, including the Victorian Export Award for Innovation Excellence.